Cited by 142Hepatocellular Carcinoma Treatment and PrognosisLiver physiology and pathologyOrgan Transplantation Techniques and Outcomes

Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization

de Baere, Thierry, Teriitehau, Christophe, Deschamps, Frederic, Catherine, Laurence, Rao, Pramod, Hakime, Antoine, Auperin, Anne, Goere, Diane +2 more·2010·Annals of Surgical Oncology

Abstract

Background To analyze predictive factors of hypertrophy of the nonembolized future remnant liver (FRL) after transhepatic preoperative portal vein embolization (PVE) of the liver to be resected.Materials and methods Age, gender, indocyanin green clearance test, chemotherapy before PVE, type of chemotherapy, operators, extent of PVE, radiofrequency ablation (RFA) associated with PVE, time delay between PVE and surgery, and platelet count were retrospectively evaluated as predictive factors for hypertrophy of FRL in 107 patients with malignant disease in noncirrhotic liver. PVE targeted the right liver lobe [n = 70] or the right liver lobe and segment IV [n = 37] when FRL/total liver volume ratio was below 25% in healthy liver or 40% in altered liver.Results After PVE, FRL volume significantly increased by 69%, from 344 +/- 156 cm(3) to 543 +/- 192 cm(3) (P < .0001). The degree of hypertrophy was negatively correlated with FRL volume (correlation coefficient = -0.55, P < .0001) and FRL/TFL ratio (correlation coefficient = -0.52, P < .0001) before PVE. Patients, who have undergone chemotherapy with platin agents prior to PVE, demonstrated lower hypertrophy (P = .048).Conclusion Hypertrophy after PVE is inversely correlated to initial FRL volume. Hypertrophy of the liver might be influenced by the systemic chemotherapeutic received before PVE.

Integrity signals

Registry

Crossref · 10.1245/s10434-010-0979-2

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Predictors of response to TACE were a size of <3 cm and high lipidol uptake.

    “Predictors of response were a size of <3 cm and high lipidol uptake.”

    From Adrenocortical carcinoma (2014) · cites this paper as [357]

  • In the largest series to date, 103 lesions in 29 patients were treated with TACE with response in 21% of patients and stabilization in 62%.

    “In the largest series to date, 103 lesions in 29 patients were treated with response in 21% of patients and stabilization in 62% (357).”

    From Adrenocortical carcinoma (2014) · cites this paper as [357]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
de Baere, T., Teriitehau, C., Deschamps, F., Catherine, L., Rao, P., Hakime, A., Auperin, A., Goere, D., Elias, D., & Hechelhammer, L.
Affiliations
Institut Gustave Roussy (FR)
Venue
Annals of Surgical Oncology
Published
2010-03-17
Volume
17
Issue
8
Pages
2081-2089
ISSN
  • 1068-9265 (ISSN-L)
  • 1534-4681
OpenAlex
W2082993378
Cited by
139
References
43
Citations by year
2026: 5 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 10 · 2020: 10 · 2019: 10 · 2018: 10 · 2017: 11 · 2016: 12 · 2015: 8 · 2014: 8 · 2013: 10 · 2012: 12
FWCI
5.24
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Surgical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
Keywords
liver hypertrophy, predictive factors, hepatectomy, non-cirrhotic liver, neoadjuvant chemotherapy, platinum agents, indocyanine green clearance, radiofrequency ablation
MeSH terms
Adolescent, Adult, Aged, Embolization, Therapeutic, Female, Hepatectomy, Humans, Hypertrophy, Liver, Liver Neoplasms, Male, Middle Aged, Portal Vein, Retrospective Studies, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review